Last reviewed · How we verify
NCT06714708
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
Phase 2 trial testing Experimental in NSCLC in 86 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | Anhui Provincial Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 86 |
| Start date | 20 November 2024 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Experimental — full drug profile →
- Active comparator — full drug profile →
Conditions studied
- NSCLC — all drugs for NSCLC →
- Neoadjuvant Immunotherapy — all drugs for Neoadjuvant Immunotherapy →
- Low Dose Radiotherapy — all drugs for Low Dose Radiotherapy →
- Sintilimab — all drugs for Sintilimab →
Sponsor
Anhui Provincial Cancer Hospital
Who can join
18 and older, any sex, with NSCLC or Neoadjuvant Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate efficacy and safety of low dose radiotherapy combined with sintilimab and platinum based chemotherapy as neoadjuvant therapy for stage II-III Non-Small Cell Lung Cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06714708
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Experimental
Trials testing the same drug.
- NCT07105943 — Manipulating Exercise Intensity and Affective Responses for Cardiac Rehabilitation Program Acute Coronary Syndrome Patie · NA · not yet recruiting
- NCT07471945 — Individualized Nursing Care and Frailty Outcomes in Cardiac Surgery · NA · not yet recruiting
- NCT07368881 — Fast Food Online Delivery Purchase Behaviour in the Presence and Absence of Price-based Incentives · NA · not yet recruiting
- NCT07300358 — Study on the Safety and Effectiveness of a Biodegradable Patent Foramen Ovale Occluder System · NA · not yet recruiting
- NCT07222774 — Strengthening Intentions · NA · active not recruiting
Other recruiting trials for NSCLC
Currently open trials in the same condition.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting
Other Anhui Provincial Cancer Hospital trials
Trials by the same sponsor.
- NCT07371871 — A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Th · NA · not yet recruiting
- NCT07299890 — An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy · Phase 2 · not yet recruiting
- NCT07330596 — QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC · Phase 2 · recruiting
- NCT07197697 — A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ · Phase 2 · not yet recruiting
- NCT07195084 — To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06714708 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Cancer Hospital
- Last refreshed: 10 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06714708.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing